

Trokendi XR® (topiramate) - First-time generic

- On January 4, 2023, <u>Zydus launched AB-rated</u> generic versions of Supernus' <u>Trokendi XR</u> (topiramate) 25 mg, 50 mg, and 100 mg extended-release capsules.
- Trokendi XR is approved as initial monotherapy for the treatment of partial-onset or primary
 generalized tonic-clonic seizures in patients 6 years of age and older; as adjunctive therapy for
 the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures
 associated with Lennox-Gastaut syndrome in patients 6 years of age and older; and for the
 preventive treatment of migraine in patients 12 years of age and older.
- Trokendi XR is also available as a brand 200 mg extended-release capsule.
- As per IQVIA data, Trokendi XR had annual sales of \$488 million in the U.S.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.